ABT- Abbott Laboratories
Healthcare · Medical Devices
Price & Performance
Performance
Analysis & Verdict
Analyst Ratings
BuyWall Street consensus from 24 analysts
12-Month Price Target
$120.21
Based on analyst estimates; price targets are opinions, not guarantees.
Fair Value Estimates
Current price: $101.95
Graham Number
√(22.5 × EPS × Book Value)
$45.32
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$34.27
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
8/10
80% score
Pays dividends
15Y hist.15+ years of dividend history
Dividend consistency (5Y+)
15 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
10.6%Return on equity - measures how efficiently capital is used
Positive profit margin
11.6%Net profit margin must be positive - company earns more than it spends
Revenue growth (annual)
+13.0%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
-47.5%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
63.21×Low financial leverage reduces risk of distress
Current ratio above 1
1.38×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$1.1B/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
2.47%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Oct 14, 2026
32
days
EPS (TTM)
$3.09
P/E (TTM)
33.0
Fwd P/E
16.8
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
2.47%
5Y Avg Annual
$2.0740
Last Payment
$0.6300
Ex-Date
07/15/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest07/15/2026 | 08/17/2026 | $0.6300 | 2.47% |
04/15/2026 | 05/18/2026 | $0.6300 | 2.47% |
01/15/2026 | 02/17/2026 | $0.6300 | 2.47% |
10/15/2025 | 11/17/2025 | $0.5900 | 2.31% |
07/15/2025 | 08/17/2025 | $0.5900 | 2.31% |
04/15/2025 | 05/18/2025 | $0.5900 | 2.31% |
01/15/2025 | 02/17/2025 | $0.5900 | 2.31% |
10/15/2024 | 11/17/2024 | $0.5500 | 2.16% |
Magic Number
Shares needed to self-fund your next purchase
$101.95
Price
$0.6300
Last div. (quarterly)
162
shares
Own 162 ABT shares ($16,515.90) and each quarterly dividend pays for 1 new share - the snowball runs on its own.
Investment target
$16,515.90
New shares / year
+4 shares
Dividend Calculator
2.47% yieldEstimate ABT dividend income at the current rate.
Per year
$247.18
Per month
$20.6
≈ 98.1 shares at $2.52/share a year. Estimate only - dividends can be cut or raised.
Tools & Simulators
ABT vs Peers, Indexes & Commodities
?Click a card below to plot it on the chart
Loading history…
Parameters
Final value
$426,404.61
Total invested
$130,000.00
Total interest
$296,404.61
Balance over time
Period breakdown
| Period | Balance | Invested | Interest |
|---|---|---|---|
| Start | $10,000.00 | $10,000.00 | $0.00 |
| Year 1 | $17,270.27 | $16,000.00 | $1,270.27 |
| Year 2 | $25,267.56 | $22,000.00 | $3,267.56 |
| Year 3 | $34,064.59 | $28,000.00 | $6,064.59 |
| Year 4 | $43,741.32 | $34,000.00 | $9,741.32 |
| Year 5 | $54,385.72 | $40,000.00 | $14,385.72 |
| Year 6 | $66,094.55 | $46,000.00 | $20,094.55 |
| Year 7 | $78,974.28 | $52,000.00 | $26,974.28 |
| Year 8 | $93,141.97 | $58,000.00 | $35,141.97 |
| Year 9 | $108,726.44 | $64,000.00 | $44,726.44 |
| Year 10 | $125,869.35 | $70,000.00 | $55,869.35 |
| Year 11 | $144,726.56 | $76,000.00 | $68,726.56 |
| Year 12 | $165,469.48 | $82,000.00 | $83,469.48 |
| Year 13 | $188,286.70 | $88,000.00 | $100,286.70 |
| Year 14 | $213,385.63 | $94,000.00 | $119,385.63 |
| Year 15 | $240,994.47 | $100,000.00 | $140,994.47 |
| Year 16 | $271,364.18 | $106,000.00 | $165,364.18 |
| Year 17 | $304,770.87 | $112,000.00 | $192,770.87 |
| Year 18 | $341,518.22 | $118,000.00 | $223,518.22 |
| Year 19 | $381,940.31 | $124,000.00 | $257,940.31 |
| Year 20 | $426,404.61 | $130,000.00 | $296,404.61 |
What is compound interest?
Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.
Which rate should I use?
The S&P 500 has historically returned ~10%/year before inflation over long periods - use this for an all-equity US index fund scenario. A balanced growth portfolio (stocks + bonds) is closer to 7%. High-yield savings accounts (HYSA) are currently paying around 4-5% with FDIC insurance and zero market risk. Bonds historically return ~4% annualized.
Formula used
FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.
For educational purposes only. Not financial advice. Past returns do not guarantee future results.
Discussion
Sign in to join the discussionSign inLoading…
Discover
Related Assets
Healthcare
Related Articles
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Sector
Healthcare
Industry
Medical Devices
Location
Abbott Park, United States
Employees
122,000
Stock Market ROI Pro
All features, zero ads- web & app
Unlock every feature, ad-free, across our website and iOS app.
Abbott Laboratories (ABT) stock trades at $101.95, down 1.36% on the day. With a market capitalization of $176.41 billion, ABT is a large-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 33.0, a forward P/E of 16.8 and earnings per share (EPS) of $3.09. Over the most recent period the company reported 13% year-over-year revenue growth and a net profit margin of 11.6%. Below you'll find ABT's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
ABT - Frequently Asked Questions
Is Abbott Laboratories (ABT) a good stock to buy in 2026?
Abbott Laboratories (ABT) shows strengths such as revenue growth of 13%, while risks include high leverage (debt/equity of 63.2). Whether ABT is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is ABT's stock price today?
Abbott Laboratories (ABT) trades at $101.95, down 1.36% on the session. Prices on this page update throughout the trading day.
Does ABT pay a dividend?
Yes. Abbott Laboratories pays an annual dividend of $2.52 per share, a dividend yield of 2.47%. The most recent ex-dividend date was July 15, 2026. Its payout ratio is about 79% of earnings.
Is ABT overvalued?
With a P/E ratio of 33.0×, ABT is valued above the broad-market average for the healthcare sector. Its PEG ratio is 1.93. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is ABT's market cap?
Abbott Laboratories (ABT) has a market capitalization of $176.41 billion, classifying it as a large-cap stock in the Healthcare sector.
Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.